Modern Pediatrics. Ukraine. (2024). 4(140): 119-125. doi: 10.15574/SP.2024.140.119
Pochynok T. V.¹, Kaplun M. N.², Lutai T. I.¹, Gorobets N. I.¹, Mukanska L. V.^2
1Bogomolets National Medical University, Kyiv, Ukraine
²Communal Non-Commercial Enterprise «Children's Clinical Hospital No. 4 of the Solomyansky District of Kyiv», Ukraine

For citation: Pochynok TV, Kaplun MN, Lutai TI, Gorobets NI, Mukanska LV. (2024). Immune complex vasculitis of small vessels with secondary glomerulonephritis in children. Modern Pediatrics. Ukraine. 4(140): 119-125. doi: 10.15574/SP.2024.140.119.
Article received: Mar 05, 2024. Accepted for publication: May 14, 2024.

Immunoglobulin A – vasculitis (IgA-V) is a systemic disease with predominant damage to the microcirculatory channel of the skin, gastrointestinal tract, joints, and kidneys.
Aim – to show, on the basis of clinical observation, the features of the symptoms and course of IgA-V when the kidneys are involved in the pathological process and the complications of treatment.
Clinical case. A 5-year-old child hospitalized with a diagnosis of acute IgA-V of moderate severity: skin, joint, abdominal forms. Bed rest, symptomatic and supportive therapy were prescribed, antigenic load was excluded, pain syndrome was controlled with acetaminophen. Positive dynamics of clinical syndromes were observed. However, against the background of bed rest on the 17th day of the illness, fresh and changed erythrocytes appeared in the morning urine, covering the entire field of vision, erythrocyte cylinders (up to 30-40), protein – 0.9 g/l. In daily urine – protein – 2.0 g/day. The absence of an increase in blood pressure (BP), edema allowed to document the isolated urinary syndrome of secondary glomerulonephritis. Taking into account the severity of the urinary syndrome, prednisolone 1 mg/kg was added to the treatment complex. The lack of effectiveness of corticosteroid for 3 weeks led to the use of plasmapheresis in the children's clinic named “Protection of motherhood and childhood”, after which the number of erythrocytes decreased to 50-80 in the field of vision, erythrocyte cylinders (to 5-8). The daily protein level is up to 1.5 g/day. The child was transferred to the nephrology department, where angiotensin-converting enzyme inhibitors were prescribed under BP control against the background of corticosteroid withdrawal. Observation of the child for 3 years showed periodic exacerbations of vasculitis, which occurred against the background of acute respiratory diseases, which were manifested by a slight hemorrhagic rash on the lower extremities and changes in urine tests. The patient's BP was within normal limits. During the last year of observation, there were no exacerbations of glomerulonephritis and no skin rashes were observed.
Conclusions. IgA – vasculitis involving the kidneys in the form of hematuria and proteinuria can have a long course. Treatment of pronounced urinary syndrome should take into account the possibility of insufficient effectiveness of corticosteroid and the need to use other treatment regimens that depend on the severity of the pathological process in the kidneys. Renoprotection with angiotensin-converting enzyme inhibitors prevents secondary kidney damage.
The research was carried out in accordance with the principles of the Declaration of Helsinki. Informed consent of the child's parents was obtained for the research.
The authors declare no conflicts of interest.
Keywords: children, immunoglobulin A – vasculitis, secondary glomerulonephritis with urinary syndrome, treatment.

References:

1. Bista S, Adhikari Y, Karmacharya S, Joshi S, Pandey S, Adhikari N. (2023). Henoch-Schönlein purpura with antecedent allergic diseases in a 4-year-old child: a case report. Ann Med Surg (Lond). 85(6): 3066-3069. https://doi.org/10.1097/MS9.0000000000000782; PMid:37363590 PMCid:PMC10289484

2. Bluman J, Goldman RD. (2014). Henoch-Schönlein purpura in children: limited benefit of corticosteroids. Can Fam Physician. 60(11): 1007-1010.

3. Cao T, Yang HM, Huang J, Hu Y. (2023). Risk factors associated with recurrence of Henoch-Schonlein purpura: a retrospective study. Front Pediatr. 11: 1164099. https://doi.org/10.3389/fped.2023.1164099; PMid:37377759 PMCid:PMC10291609

4. Guo D, Lam JM. (2016). Henoch-Schönlein purpura. CMAJ. 188(15): 393. https://doi.org/10.1503/cmaj.151072; PMid:27431304 PMCid:PMC5056890

5. Hetland LE, Susrud KS, Lindahl KH, Bygum A. (2017). Henoch-Schönlein Purpura: A Literature Review. Acta Derm Venereol. 97(10): 1160-1166. https://doi.org/10.2340/00015555-2733; PMid:28654132

6. Jennette JC, Falk RJ, Bacon PA et al. (2013). 2012-revised International Сhapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65(1): 1-11. https://doi.org/10.1002/art.37715; PMid:23045170

7. Liu Y, Jesus AA, Marrero B et al. (2014). Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371(6): 507-518. https://doi.org/10.1056/NEJMoa1312625; PMid:25029335 PMCid:PMC4174543

8. Liu Y, Ramot Y, Torrelo A et al. (2012). Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic phenotypic heterogeneity. Arthritis Rheum. 64(3): 895-907. https://doi.org/10.1002/art.33368; PMid:21953331 PMCid:PMC3278554

9. Navon EP, Pierce SB, Segel R et al. (2014). Mutant adenosine deaminase 2 in polyarteritis nodosa vasculopathy. N. Engl. J Med. 370(10): 921-931. https://doi.org/10.1056/NEJMoa1307362; PMid:24552285

10. Nguyen B, Acharya C, Tangpanithandee S, Miao J, Krisanapan P, Thongprayoon C et al. (2023). Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review. Int J Mol Sci. 16; 24(4). https://doi.org/10.3390/ijms24043977

11. Nikolaishvili M, Pazhava A, Di Lernia V. (2023). Viral Infections May Be Associated with Henoch-Schönlein Purpura. J. Clin. Med. 16; 12(2). https://doi.org/10.3390/jcm12020697; PMid:36675626 PMCid:PMC9862009

12. Ozen S, Marks SD, Brogan P et al. (2019). European consensus based recommendations for diagnosis and treatment of immunoglobulin A vasculitis – the SHARE initiative. Rheumatology (Oxford). 58(9): 1607-1616. https://doi.org/10.1093/rheumatology/kez041; PMid:30879080

13. Ozen S, Pistirio A, Iusan SM et al. (2010). EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008/ Part II: final classification crsteria. Ann. Rheum. Dis. 69: 798-806. https://doi.org/10.1136/ard.2009.116657; PMid:20413568

14. Piram M, Mahr A. (2013). Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein) current state of knowledge. Curr. Opin. Rheumatol. 25: 171-178. https://doi.org/10.1097/BOR.0b013e32835d8e2a; PMid:23318735

15. Piram M, Maldini C, Biscardi S et al. (2017). Incidence of Ig A vasculitis in children estimated by four – source capture – recapture analysis: a population – based study. Rheumatology (Oxford). 56: 1358-1366. https://doi.org/10.1093/rheumatology/kex158; PMid:28444335

16. Popov H, Koleva T, Stoyanov GS. (2023). Bullous Henoch-Schönlein Purpura and Associated Nephritis: A Pathological Case Report. Cureus. 15(2): 35051. https://doi.org/10.7759/cureus.35051

17. Rajasekaran A, Julian BA, Rizk DV. (2021). IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 361(2): 176-194. https://doi.org/10.1016/j.amjms.2020.10.003; PMid:33309134 PMCid:PMC8577278

18. Reamy BV, Williams PM, Lindsay TJ. (2009). Henoch-Schönlein purpura. Am. Fam. Physician. 80(7): 697-704.

19. Salem Y, Alam Z, Shalabi MM, Hosler GA, Acharya S. (2023). IgA Vasculitis Associated With COVID-19. Cureus. 15(5): 38725. https://doi.org/10.7759/cureus.38725

20. Sestan M, Jelusic M. (2023). Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives. Pediatric Health Med Ther. 14: 89-98. https://doi.org/10.2147/PHMT.S379862; PMid:36915829 PMCid:PMC10008002

21. Sugino H, Sawada Y, Nakamura M. (2021). IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int. J. Mol. Sci. 22(14). https://doi.org/10.3390/ijms22147538; PMid:34299162 PMCid:PMC8307949

22. Trnka P. (2013). Henoch-Schönlein purpura in children. J Paediatr Child Health. 49(12): 995-1003. https://doi.org/10.1111/jpc.12403; PMid:24134307

23. Xu L, Li Y, Wu X. (2022). IgA vasculitis update: Epidemiology, pathogenesis, and biomarkers. Front Immunol. 13: 921864. https://doi.org/10.3389/fimmu.2022.921864; PMid:36263029 PMCid:PMC9574357

24. Zhou Q, Yang D, Ombrello AK et al. (2014). Early – onset strok and vasculopathy associated with mutation in ADA2. N. Engl. J Med. 370(10): 911-920.